209 results about "Heavy-chain antibody" patented technology

The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation. It further relates to protocols for screening for agents that modulate the Epidermal Growth Factor Receptor, and the agents resulting from said screening. The invention further a method for delivering therapeutic molecules to the interior of cells

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to interferon gamma. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the IFN-gamma receptor, and the agents resulting from said screening.

The invention relates to a single-domain heavy chain antibody and polypeptide for Listeria monocytogenes. The antibody has the protein or polypeptide with the amino acid sequence disclosed as SEQ ID NO:1, and can be used in the fields of immune detection, antigen enrichment purification and the like. The amino acid sequence provided by the invention can be used as a precursor, can be modified by using a random or site-directed mutagenesis technique to obtain a mutant with better properties (affinity, specificity, stability and the like), and is used for developing proteins or polypeptides which are further used in medicine, industry and agriculture.

The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework β-pleated sheet leading to increased net hydrophobicity within FR1 and an increased number of charged amino acids present in FR3. Also provided are VII domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.

The invention belongs to the technical field of biology, and relates to a camel source immunity nanometer antibody (single-domain heavy-chain antibody, VHH) specifically bound with AFP and application of the antibody. The amino acid sequence of the antibody is SEQ ID NO.:1. The invention further relates to nucleotides for encoding amino acids. The AFP nanometer antibody can be used as the antibody to be applied to immunological detection of AFP not for disease diagnosis and treatment. Compared with a Scfv antibody and a Fab antibody, the camel source immunity VHH has the higher specificity and affinity, more stable in structure, resistant to acid, base and high temperature, high in detection flexibility and the like, so that the immunity detection stability is greatly improved, and meanwhile the environment resistance is greatly improved.

The invention relates to a specific PRRS (Porcine Reproductive and Respiratory Syndrome) virus non-structural protein Nsp9 nanobody and discloses a VHH (Variable Domain of Heavy-chain Antibody) sequence of the nanobody and a DNA sequence encoding the nanobody at the same time. The invention further provides an expression vector which can express nanobody-eGFP fusion protein in an Marc145 cell. The Nsp9 nanobody can be specifically bound with PRRS virus non-structural protein Nsp9, and has functions of inhibiting multiplication of a classic strain and a highly pathogenic strain of a PRRS virus in the Marc-145 cell. The nanobody can be developed into a drug for treating a PRRS, and a gene corresponding to the nanobody can be used for development of a PRRS resistance transgenic pig.

The invention discloses a bactrian camel heavy-chain (HC) variable-domain antibody resisting a porcine circovirus 2 as well as a preparation method and an application thereof, and belongs to the field of a biotechnology. A PCV2 (Porcine Circovirus Virus) inactivated vaccine immunized bactrian camel is firstly utilized and a phage display technology is utilized to establish a PCV2 immune VHH antibody base; and a high-specificity variable domain antibody of heavy chains of HCAbs (VHH) which has a good affinity with the PCV, particularly a PCV2 virus antigen; and the antibody disclosed by the invention has an amino acid sequence shown as SEQ (sequence) ID NO.1 or an amino acid sequence which is shown as SEQ ID NO.2 and has the sequence isogeny being more than 95%. The PCV2 heavy-chain variable-domain antibody disclosed by the invention has the very important meanings on researching porcine circovirus, particularly researching a porcine circovirus 2-type infection mechanism and establishing rapid antigen detection with high sensitivity and specificity or diagnosing a reagent.

The invention belongs to the technical field of biology, and relates to an immunoaffinity adsorption material based on a single-domain heavy-chain antibody, in particular to an immunoaffinity adsorption material for aflatoxin. The material comprises a carrier and a ligand carried by the carrier, and is characterized in that the single-domain heavy-chain antibody specially recognizing aflatoxin is used as the ligand and has the amino acid sequence shown in SEQ ID NO.:1and the like. The antibody has the advantages of being resistant to acid, alkali and high temperature, easy to produce and the like, and important practical value is achieved for a low-cost immunological detection method which is used for aflatoxin and can be repeatedly used.

The present invention relates to a method for producing a functional human immunoglobulin, wherein a human heavy chain immunoglobulin, devoid of any light chain, is expressed, comprising the steps of: a) transforming a filamentous host cell with a recombinant construct encoding a modified human heavy chain immunoglobulin, wherein the modifications comprise one or more mutations in the region of the heavy chain protein involved in contact with the light chain; b) culturing said filamentous host cell under conditions promoting expression of said modified human heavy chain immunoglobulin; and c) recovering said modified human heavy chain immunoglobulin.

The invention relates to the technical field of biology, in particular to a nano-antibody GN1 specifically combined with a GPC3 protein. The nano-antibody GN1 is composed of a variable region of a heavy-chain antibody, the variable region of the heavy-chain antibody comprises an antigenic determinant complementary region and a skeleton region, the skeleton region is selected from the group consisting of FR1, FR2, FR3 and FR4 and homologous sequences thereof, the antigenic determinant complementary region is selected from the group consisting of CDR1, CDR2 and CDR3 and homologous sequences thereof, the amino acid sequences of the CDR1 to the CDR3 are shown in the formulas of SEQ ID NO. 1 to SEQ ID NO. 3, the amino acid sequences of the FR1-4 are shown in formulas of SEQ ID NO. 4-7, the amino acid sequence of the antibody is shown in the formula of SEQ ID NO.8, and the nucleotide sequence for encoding the amino acid is shown in the formula of SEQ ID NO.9. The nano-antibody GN1 can be specifically combined with hepatoma carcinoma cells highly expressing the GPC3 protein to inhibit hepatoma carcinoma cell proliferation. The amino acid sequence of the nano-antibody GN1 or the nucleotidesequence of the nano-antibody GN1 or the recombinant plasmid containing the nucleotide sequence of the nano-antibody GN1 or the recombinant cell containing the recombinant plasmid containing the nucleotide sequence of the nano-antibody GN1 can be applied to research and development of diagnostic reagents and drugs for treating liver cancer.

Provided are isolated and purified preparations of a combination of a light chain antibody gene and a heavy chain antibody gene, where the light chain and heavy chain antibody genes are the same among more than one patient with B cell chronic lymphocytic leukemia (B-CLL). Vectors comprising those genes and cells comprising those vectors are also provided, as are isolated and purified antibodies encoded by the antibody genes. Anti-idiotype antibodies, peptides, and aptamers that bind to the antigen-binding region of an antibody encoded by the antibody genes are additionally provided, as are multimeric molecules comprising multiple binding sites that bind to the antigen-binding region of an antibody encoded by the antibody genes. Methods of determining whether a patient with B cell chronic lymphocytic leukemia (B-CLL) has a form of B-CLL that is susceptible to treatment directed to eliminating idiotype specific B cell receptor-bearing B-CLL cells are also provided, as are methods of following the progression of treatment of B-CLL in the patient. Additionally, methods of treating a patient having B-CLL are provided, as are methods of identifying a therapeutic agent for B-CLL.

The present invention relates to a nanobody GN2 composed of a variable region of a heavy chain antibody; and the variable region of the heavy chain antibody comprises an epitope complementary region selected from a group consisting of CDR1, CDR2 and CDR3 and homologous sequences of the CDR1, CDR2 and CDR3 and a skeleton region selected from a group consisting of FR1, FR2, FR3 and FR4 and homologous sequences of the FR1, FR2, FR3 and FR4. The present invention also relates to a preparation method and an application of the nanobody GN2. The nanobody GN2 can specifically bind to hepatocarcinoma cells that highly express GPC3 protein, inhibits hepatocarcinoma cell proliferation, and is small in molecular weight, stable in structure, good in heat resistance, high in affinity, easy for storage and transportation, weak in immunogenicity to human body, also strong in tumor tissue penetrating power, liable to express and genetically engineered, and particularly suitable for use as a diagnosticreagent or a therapeutic antibody. The method can retain more antigen epitopes, and is high in carrier quality, good in an enzyme digestion effect, high in connection efficiency, low in self-connection efficiency and also low in cost.

The invention belongs to the field of genetic engineering and particularly relates to a single-domain heavy chain antibody specific to a histidine label, having an amino acid sequence shown as in SEQ ID NO: 1 and applicable to the fields such as immunodetection and antigen enrichment and purification. The amino acid sequence provided herein may function as a precursor, and by modifying through random or fixed-point mutation technology, it is possible to obtain a mutant with better properties (affinity, specificity, stability and the like), and the mutant is useful to develop proteins or polypeptides applied to medicine, industry and agriculture.

The invention relates to a single-domain heavy chain antibody aiming at anti-prostate specific membrane antigen, which belongs to the field of gene engineering. The antibody has the protein with the amino acid sequence disclosed as SEQ ID NO:1, and can be used in the fields of immune detection, antigen enrichment purification and the like. The amino acid sequence provided by the invention can be used as a precursor, can be modified by using a random or site-directed mutagenesis technique to obtain a mutant with better properties (affinity, specificity, stability and the like), and is used for developing proteins or polypeptides which are further used in medicine, industry and agriculture.

The invention discloses a bactrian camel VHH (variable domain of the heavy chain of HACbs) heavy-chain antibody for resisting foot-and-mouth disease AsiaI type viruses, a preparation method and use thereof, belonging to the field of biotechnology. In the method, recombinant AsiaI type virus-like particle antigens are used for immunizing bactrian camels; an AsiaI VHH immune antibody library is established with phage display technology; high-specificity single-domain antibodies having good affinity with foot-and-mouth disease AsiaI type virus antigens are screened; the antibody provided by the invention has amino acid sequence shown by SEQ ID NO.1 or amino acid sequence which has sequence homology more than 98% with the sequence shown by SEQ ID NO.1. The AsiaI VHH heavy-chain antibody provided by the invention has great importance for researching AsiaI type virus infection mechanisms and producing high-sensitive and specific antigen fast detection or diagnosis reagents.

The invention provides an immunoglobulin Fc (fragment crystalline) targeted single-domain heavy-chain antibody with has amino acid sequence shown in SEQ ID NO.: 1 and contains four framework regions and three complementarity-determining regions, wherein the framework regions are respectively selected from SEQ ID NO.: 2, SEQ ID NO.: 4, SEQ ID NO.: 6 and SEQ ID NO.: 8, and the complementarity-determining regions are respectively selected from SEQ ID NO.: 3, SEQ ID NO.: 5 and SEQ ID NO.: 7. The invention also relates to nucleic acid for coding the single-domain heavy-chain antibody and polypeptide and a method for preparing the single-domain heavy-chain antibody and polypeptide. The single-domain heavy-chain antibody and polypeptide can be used for preparing regents or materials for testing or purifying antibodies.

The invention belongs to the technical field of biology, and relates to a camel source immunity nanometer antibody (single-domain heavy-chain antibody, VHH) specifically bound with AFP and application of the antibody. The amino acid sequence of the antibody is SEQ ID NO.:1. The invention further relates to nucleotides for encoding amino acids. The AFP nanometer antibody can be used as the antibody to be applied to immunological detection of AFP not for disease diagnosis and treatment. Compared with a Scfv antibody and a Fab antibody, the camel source immunity VHH has the higher specificity and affinity, more stable in structure, resistant to acid, base and high temperature, high in detection flexibility and the like, so that the immunity detection stability is greatly improved, and meanwhile the environment resistance is greatly improved.

The invention discloses a porcine reproductive and respiratory syndrome virus Nsp2 protein nano-antibody and an application thereof. The nano-antibody is named Nb12, and the amino acid sequence of thenano-antibody is represented by SEQ ID NO.3. A camel is immunized with a truncated expression Nsp2 recombinant protein, camel peripheral blood lymphocytes are separated, and an immunized bactrian camel VHH gene is amplified by using RT-PCR, the amplified gene is connected into a pCANTAB 5E phage vector to construct a bactrian camel heavy chain antibody variable region library, 44 Nsp2 specific nano-antibodies are screened out through three rounds of panning by utilizing a phage display technology, tests prove that the nano-antibodies can specifically react with a Nsp2 protein, and the Nb12 has strong binding force. Antiviral test results show that when the virus inoculation amount is 0.01 MOI, the nano-antibody Nb12 shows a virus replication inhibition effect on both PAM cells and Marc-145 cells. Therefore, a new technical means is provided for subsequent research of the PRRSV Nsp2 and prevention, control and diagnosis of the PRRSV.